AIEOP2017 observational protocol for the treatment of children and adolescents with acute lymphob...
Children and adolescents with acute non-B mature lymphoblastic leukaemia, between 1 and 18 years of age diagnosed after the completion of the AIEOP-BFM ALL 2009 protocol will continue to follow the eligibility and stratification criteria described in the previous protocol. Therefore, the observational study includes the collection of data on the biological characteristic and the evaluation of response to treatment ( prednisone and post-induction response, minimal residual disease).
In the AIEOP LLA 2017 observational study, patients with LLA are treated according to the AIEOP LLA 2009 study arm control scheme, assumed as the "best standard of therapy".
This job comes from a partnership with Science Magazine and